AR082314A1 - Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular - Google Patents

Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular

Info

Publication number
AR082314A1
AR082314A1 ARP110102644A ARP110102644A AR082314A1 AR 082314 A1 AR082314 A1 AR 082314A1 AR P110102644 A ARP110102644 A AR P110102644A AR P110102644 A ARP110102644 A AR P110102644A AR 082314 A1 AR082314 A1 AR 082314A1
Authority
AR
Argentina
Prior art keywords
antibody
activated form
enhanced activated
pharmaceutical composition
vascular
Prior art date
Application number
ARP110102644A
Other languages
English (en)
Spanish (es)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of AR082314A1 publication Critical patent/AR082314A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
ARP110102644A 2010-07-21 2011-07-21 Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular AR082314A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство

Publications (1)

Publication Number Publication Date
AR082314A1 true AR082314A1 (es) 2012-11-28

Family

ID=44899157

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102644A AR082314A1 (es) 2010-07-21 2011-07-21 Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular

Country Status (23)

Country Link
US (1) US20130058981A1 (enExample)
EP (1) EP2596018A2 (enExample)
JP (2) JP2013536174A (enExample)
KR (1) KR20130102542A (enExample)
CN (1) CN103124741A (enExample)
AR (1) AR082314A1 (enExample)
AU (1) AU2011281248B2 (enExample)
BR (1) BR112013001296A2 (enExample)
CA (1) CA2805985A1 (enExample)
CL (1) CL2013000201A1 (enExample)
DE (1) DE112011102397T5 (enExample)
EA (1) EA029998B1 (enExample)
ES (1) ES2446643R1 (enExample)
FR (1) FR2962910A1 (enExample)
GB (1) GB2496342B (enExample)
IL (1) IL224336A (enExample)
IT (1) ITTO20110630A1 (enExample)
MX (1) MX355371B (enExample)
NZ (1) NZ606988A (enExample)
PE (1) PE20131065A1 (enExample)
PH (1) PH12013500141A1 (enExample)
SG (2) SG187160A1 (enExample)
WO (1) WO2012010974A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
ITTO20110641A1 (it) 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
EP3693018A1 (en) * 2010-07-21 2020-08-12 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
CA2805963A1 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
GB2496801B (en) * 2010-07-21 2018-04-11 Iliich Epshtein Oleg A method of treating alzheimer's disease
PH12013500142A1 (en) 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2012017328A2 (en) * 2010-08-06 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2518965C (en) * 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
ITTO20110641A1 (it) * 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
US8637034B2 (en) * 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
PH12013500142A1 (en) * 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
EP3693018A1 (en) * 2010-07-21 2020-08-12 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
GB2496801B (en) * 2010-07-21 2018-04-11 Iliich Epshtein Oleg A method of treating alzheimer's disease
CA2805963A1 (en) * 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
ITTO20110634A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Metodo per trattare patologie organiche del sistema nervoso, la sindrome psicoorganica e l'encefalopatia

Also Published As

Publication number Publication date
BR112013001296A2 (pt) 2017-12-19
CA2805985A1 (en) 2012-01-26
PE20131065A1 (es) 2013-09-23
ES2446643R1 (es) 2015-03-06
PH12013500141A1 (en) 2013-03-11
EP2596018A2 (en) 2013-05-29
ITTO20110630A1 (it) 2012-01-22
NZ606988A (en) 2015-08-28
CL2013000201A1 (es) 2015-01-23
FR2962910A1 (fr) 2012-01-27
WO2012010974A8 (en) 2013-04-25
KR20130102542A (ko) 2013-09-17
GB2496342B (en) 2017-12-06
AU2011281248A1 (en) 2013-03-14
WO2012010974A3 (en) 2012-04-19
MX2013000805A (es) 2013-10-28
AU2011281248B2 (en) 2017-02-02
EA201300127A1 (ru) 2013-12-30
IL224336A (en) 2017-06-29
SG187160A1 (en) 2013-02-28
JP2013536174A (ja) 2013-09-19
GB201302925D0 (en) 2013-04-03
ES2446643A2 (es) 2014-03-10
DE112011102397T5 (de) 2013-05-08
SG10201505676RA (en) 2015-08-28
WO2012010974A2 (en) 2012-01-26
MX355371B (es) 2018-04-17
US20130058981A1 (en) 2013-03-07
JP2016199571A (ja) 2016-12-01
EA029998B1 (ru) 2018-06-29
CN103124741A (zh) 2013-05-29
GB2496342A (en) 2013-05-08

Similar Documents

Publication Publication Date Title
AR082246A1 (es) Composicion farmaceutica de anticuerpo a receptor cannabinoide humano
AR118047A2 (es) Anticuerpo aislado o fragmento del mismo, composición farmacéutica y molécula biespecífica
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
MX2023014569A (es) Anticuerpos anti-sirpa.
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CL2016001405A1 (es) A peptide mixture
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
AR076195A1 (es) Anticuerpos biespecificos anti-erbb-1/anti-c-met
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
UY37635A (es) Anticuerpos anti phf-tau y sus usos
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
CL2011002831A1 (es) Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo.
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
MX2018013517A (es) Anticuerpos anti-il-1r3 humanizados.
CL2012003283A1 (es) Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8.
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
EA201071300A1 (ru) Антитела к cxcr4
EA201990298A1 (ru) Способы и композиции для лечения рака
UA112755C2 (uk) Метод лікування синдрому дефіциту уваги і гіперактивності
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit

Legal Events

Date Code Title Description
FB Suspension of granting procedure